Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy…
13 analysts rate BAX Hold on consensus.
Consensus price target: $27.92 (+10.2% upside from $25.34)
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $11.24B | +5.72% | $-957M |
| 2024 | $10.64B | +2.66% | $-649M |
| 2023 | $10.36B | +3.01% | $2.66B |
Stock data for BAX: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics